No products in the cart.
Pre-Made Choriogonadotropin Beta Biosimilar, Recombinant Protein targeting LHCGR: Recombinant therapeutic protein targeting HHG/LCGR/LGR2/LH/CG-R/LH/CGR/LHR/LHRHR/LSH-R/ULG5 for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-778
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Choriogonadotropin Beta Biosimilar, Recombinant Protein targeting LHCGR: Recombinant therapeutic protein targeting HHG/LCGR/LGR2/LH/CG-R/LH/CGR/LHR/LHRHR/LSH-R/ULG5 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Choriogonadotropin subunit beta (CG-beta) also known as chorionic gonadotrophin chain beta. CG is produced by the trophoblastic cells of the placenta and stimulates the ovaries to synthesize the steroids that are essential for the maintenance of pregnancy.
| Products Name (INN Index) | Pre-Made Choriogonadotropin Beta Biosimilar, Recombinant Protein targeting LHCGR: Recombinant therapeutic protein targeting HHG/LCGR/LGR2/LH/CG-R/LH/CGR/LHR/LHRHR/LSH-R/ULG5 |
|---|---|
| INN Name | choriogonadotropin beta |
| Target | LHCGR |
| Format | Recombinant Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | chorionic gonadotropin |
| VD LC | chorionic gonadotropin |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Ferring Pharmaceuticals (Saint-Prex Switzerland) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | LHCGR |
| Package |
Previous slide
Next slide
